arrow
M

Marc-Oliver Grimm

Jena University Hospital
H指数:53
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

85 LITESPARK-033(NCT07227402)III期研究:比较贝舒替班联合赞赞林替尼与卡博赞替尼治疗接受辅助抗PD-(L)1治疗后复发透明细胞肾细胞癌的疗效

2026-09-020
OAAI
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review

乳头状肾细胞癌——基于中央病理学审查的SUNNIFORECAST试验探索性结果:比较伊匹木单抗联合纳武利尤单抗与标准护理作为一线治疗的疗效

2026-05-270
OAAI
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

既往与同期糖皮质激素和抗生素治疗对免疫治疗疗效的差异化影响——德国AIO研究组RAMONA、INTEGA、OPTIM、ELDORANDO、FORCE、TITAN-RCC和TITAN-TCC试验的合并分析

2026-05-190
OAAI
Prostate Artery Embolization vs. Holmium Laser Enucleation of the Prostate: A Matched Pair Analysis of Functional Outcomes and Complications

前列腺动脉栓塞术与前列腺holmium激光剜除术:功能结局与并发症的配对分析

2026-03-040
OAAI
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial☆

纳武利尤单抗联合伊匹木单抗与舒尼替尼用于晚期肾细胞癌一线治疗的疗效和安全性:III期CheckMate 214试验的最终分析

2026-03-030
OAAI
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS

先前通过根治性前列腺切除术或放疗进行的局部治疗对达鲁柳胺治疗的ARAMIS患者的疗效和生活质量的影响

2025-12-260
OAAI
Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer—A Comparative Multireader Multicase Accuracy Study

人工智能辅助的双参数MRI在前列腺癌检测中的应用——一项比较性多读者多病例准确率研究

2025-08-290
OA
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial

辅助性纳武利尤单抗在肌肉浸润性尿路上皮癌中的应用:随机III期CheckMate 274试验的探索性生物标志物分析

2025-08-070
PRE
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

转移性激素敏感性前列腺癌患者接受达罗他胺或安慰剂联合多西他赛和雄激素剥夺疗法的治疗后进展生存期:ARASENS III期试验的事后分析

2025-06-200
OAAI
Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue (vol 18, e0287651, 2023)

动态对比增强磁共振成像的最佳长度和时间分辨率,用于区分前列腺癌与正常外周带组织(vol 18, e0287651, 2023)

2025-04-220
OA